SCHEMBL4665721

SCHEMBL4665721

C1=C\CC/C=C\CC/1.CN(C)p1oc2ccc3ccccc3c2c2c(ccc3ccccc32)o1.CN(C)p1oc2ccc3ccccc3c2c2c(ccc3ccccc32)o1.F[B-](F)(F)F.[Rh+]

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 4/20 0.34
▸ L3MBTL1 Q9Y468 3/20 0.33
▸ AHR P35869 3/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP1A1 P04798 1/20 0.33
▸ FYN P06241 1/20 0.33
▸ MAPK3 P27361 1/20 0.33
▸ PAX8 Q06710 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HNF4A P41235 1/20 0.32
▸ KMT2A Q03164 2/20 0.31
▸ KDM4E B2RXH2 3/20 0.31
▸ CYP3A4 P08684 2/20 0.31
▸ HPGD P15428 2/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ MAPT P10636 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29424688 0.86 HNF4A (0.40) ABCG2L3MBTL1AHRCYP1A2CYP1A1
SCHEMBL973485 0.86 HNF4A (0.40) ABCG2L3MBTL1AHRCYP1A2CYP1A1
SCHEMBL14144340 0.77 TDP1 (0.37) ABCG2L3MBTL1TDP1HNF4AKMT2A
SCHEMBL21703409 0.77 HNF4A (0.31) HNF4AKMT2A
SCHEMBL23278801 0.74 ABCG2 (0.33) ABCG2AHRCYP1A2CYP1A1FYN
SCHEMBL12808381 0.74 HNF4A (0.38) ABCG2L3MBTL1AHRCYP1A2CYP1A1
SCHEMBL11988006 0.74 ALDH1A1 (0.35) ABCG2L3MBTL1AHRCYP1A2CYP1A1
SCHEMBL12964437 0.74 TDP1 (0.38) ABCG2L3MBTL1AHRCYP1A2CYP1A1
SCHEMBL14001440 0.73 KMT2A (0.40) ABCG2L3MBTL1AHRCYP1A2CYP1A1
SCHEMBL16676464 0.72 KMT2A (0.43) ABCG2L3MBTL1AHRCYP1A2CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670583-B1 PROCESS FOR PREPARING CATIONIC RHODIUM COMPLEXES DOW GLOBAL TECHNOLOGIES INC (US) 2008-08-13 — — EP disclosed
US-7301039-B2 Process for preparing cationic rhodium complexes DOW GLOBAL TECHNOLOGIES INC. (US) 2007-11-27 — — US disclosed
US-20070004928-A1 Process for preparing cationic rhodium complexes RAMSDEN JAMES A 2007-01-04 — — US disclosed
EP-1670583-A1 PROCESS FOR PREPARING CATIONIC RHODIUM COMPLEXES DOW GLOBAL TECHNOLOGIES INC. (US) 2006-06-21 — — EP disclosed
WO-2005032712-A1 PROCESS FOR PREPARING CATIONIC RHODIUM COMPLEXES DOW GLOBAL TECHNOLOGIES INC. (US) 2005-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004928-A1 Process for preparing cationic rhodium complexes RDX, RXFP1, SDF4 ABCG2 3324/4885L3MBTL1 4417/4885AHR 4293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback